A Double-Blind, Randomized, Parallel, Placebo-Controlled, Multicenter Study Evaluating the Effect of Treatment With Topically Administered Oxybutynin Gel in Patients With Urinary Frequency, and Urge and Mixed Urinary Incontinence With a Predominance of Urge Incontinence Episodes With an Open-Label Extension.

Trial Profile

A Double-Blind, Randomized, Parallel, Placebo-Controlled, Multicenter Study Evaluating the Effect of Treatment With Topically Administered Oxybutynin Gel in Patients With Urinary Frequency, and Urge and Mixed Urinary Incontinence With a Predominance of Urge Incontinence Episodes With an Open-Label Extension.

Completed
Phase of Trial: Phase III

Latest Information Update: 20 Jul 2012

At a glance

  • Drugs Oxybutynin (Primary)
  • Indications Mixed incontinence; Overactive bladder; Urge incontinence
  • Focus Registrational; Therapeutic Use
  • Most Recent Events

    • 24 May 2012 Results presented at the 107th Annual Meeting of the American Urological Association.
    • 09 Dec 2011 Oxybutynin transdermal gel was approved by the US FDA for the treatment of overactive bladder based on the results from this trial, according to an Antares media release.
    • 18 Jan 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top